Deferoxamine: Iron Chelation, Mechanisms & Lab Uses

Deferoxamine is a naturally derived siderophore and potent hexadentate iron-chelating agent widely used in research laboratories to study iron metabolism, ferroptosis, and hypoxia-related signaling pathways.

Chemical Name

Deferoxamine (also known as desferrioxamine B or DFO)

Molecular Origin

Natural siderophore isolated from Streptomyces pilosus

Chelation Selectivity

High selectivity for Fe³⁺ and Al³⁺; forms stable 1:1 octahedral complexes (ferrioxamine)

Solubility

Freely soluble in water; typically prepared as aqueous stock solutions

Primary Research Applications

Ferroptosis inhibition, hypoxia-inducible factor (HIF) pathway activation, iron overload models, and reactive oxygen species (ROS) suppression

SKU

D1499560 (Aladdin Scientific)

Chemical Properties and Structure

Deferoxamine (DFO) is a linear, trihydroxamic acid siderophore originally isolated from the soil bacterium Streptomyces pilosus. Its backbone contains three hydroxamate functional groups arranged to coordinate a single ferric iron (Fe³⁺) ion through six oxygen donor atoms, forming a thermodynamically stable octahedral complex known as ferrioxamine. The stability constant (log K) for the Fe³⁺–DFO complex is exceptionally high, conferring strong selectivity for trivalent metal ions. DFO also chelates aluminum (Al³⁺) with clinically and experimentally relevant affinity, while showing negligible binding to physiologically important divalent cations such as Ca²⁺, Mg²⁺, and Zn²⁺ at therapeutic concentrations.

The mesylate salt form (deferoxamine mesylate) is the most commonly supplied research-grade material due to its superior aqueous solubility and stability. Stock solutions prepared in sterile water or phosphate-buffered saline (PBS) are stable for several weeks when stored at –20 °C protected from light.

Mechanism of Action in Research Models

Iron depletion and ROS suppression: Free intracellular iron participates in Fenton-type reactions that generate highly reactive hydroxyl radicals from hydrogen peroxide, contributing to oxidative stress and lipid peroxidation. By sequestering the labile iron pool (LIP), DFO interrupts this cycle and reduces cellular ROS burden. This property makes it a mechanistic control reagent in oxidative stress experiments.

Ferroptosis inhibition: Ferroptosis is a form of regulated cell death dependent on iron-driven lipid peroxidation. DFO is routinely used as a positive inhibitor control in ferroptosis assays: its iron chelation prevents the iron-catalyzed peroxidation of polyunsaturated fatty acids (PUFAs) in the plasma membrane, thereby blocking ferroptotic death. It complements lipophilic antioxidants such as ferrostatin-1 in mechanistic dissection of the ferroptosis pathway.

HIF pathway activation (chemical hypoxia): Prolyl hydroxylase domain (PHD) enzymes require Fe²⁺ and molecular oxygen to hydroxylate hypoxia-inducible factor 1-alpha (HIF-1α), targeting it for proteasomal degradation. DFO chelates iron from the PHD active site, pharmacologically mimicking hypoxia and stabilizing HIF-1α even under normoxic conditions. This chemical hypoxia approach is widely used to study HIF target gene expression, angiogenesis signaling, and ischemia-reperfusion biology without requiring a hypoxia chamber.

Experimental Applications and Protocols

Ferroptosis assays: DFO is typically applied at concentrations ranging from 100 µM to 1 mM in cell culture media, added 1–2 hours prior to or concurrently with ferroptosis-inducing agents (e.g., erastin, RSL3, or ferric ammonium citrate). Cell viability, lipid peroxidation (C11-BODIPY or MDA assay), and GSH levels serve as readouts.

Chemical hypoxia / HIF-1α stabilization: Concentrations of 100–500 µM DFO in complete cell culture medium for 4–24 hours are commonly reported for HIF-1α protein stabilization. Western blotting for HIF-1α and downstream targets (VEGF, LDHA, GLUT1) or qRT-PCR for HIF target genes confirms pathway activation. Researchers should titrate DFO dose and duration to avoid cytotoxicity at prolonged high-dose exposures.

Iron overload rescue models: In cellular models of iron overload induced by ferric ammonium citrate or hemin, DFO co-treatment can rescue viability, reduce ROS, and normalize mitochondrial membrane potential. These models are relevant to hemochromatosis, sickle cell disease, and thalassemia research.

In vivo applications: While clinical administration is subcutaneous or intravenous, research groups employ intraperitoneal injection in rodent models at doses reported in the literature. Researchers are advised to consult current literature and institutional IACUC protocols before in vivo use.

Storage, Handling, and Safety Considerations

Storage: Store deferoxamine powder at –20 °C in a tightly sealed container, protected from light and moisture. Prepared aqueous solutions should be aliquoted to minimize freeze-thaw cycles and stored at –20 °C for short-term or –80 °C for long-term use.

Preparation: Dissolve the powder in sterile, ultrapure water or PBS to prepare stock solutions (typically 10–100 mM). Filter-sterilize (0.22 µm) prior to cell culture use. Avoid DMSO as the primary solvent, as DFO is highly water-soluble and DMSO may introduce confounding effects in iron and ROS studies.

Safety: DFO is classified as an irritant. Avoid inhalation of dust and contact with eyes and skin. Use appropriate personal protective equipment (lab coat, nitrile gloves, safety glasses) when handling. Dispose of DFO-containing waste in accordance with local institutional and regulatory guidelines. No specific acute hazard is associated with research-scale handling, but standard laboratory biosafety practices apply.

Experimental controls: Always include an iron-supplementation rescue control (e.g., ferric ammonium citrate or holotransferrin) to confirm that observed phenotypes are iron-dependent and specifically reversed by iron repletion, validating DFO's on-target mechanism in each experimental system.

Reagent Selection and Quality Considerations

When selecting deferoxamine for research use, purity and counterion form are critical parameters. Research-grade DFO is most commonly supplied as the mesylate salt (deferoxamine mesylate), which offers >98% purity by HPLC. Researchers should verify the certificate of analysis (CoA) for identity confirmation (typically by NMR or mass spectrometry), purity, water content (Karl Fischer), and residual solvent levels.

Lot-to-lot consistency is particularly important for quantitative studies such as IC₅₀ determination in ferroptosis assays or EC₅₀ for HIF-1α stabilization. Aladdin Scientific's D1499560 provides a consistent, well-characterized research-grade source suitable for in vitro cell biology, biochemical assays, and preclinical model studies.

For bulk or GMP-adjacent requirements, contact your supplier's technical team to discuss documentation, endotoxin testing, and custom formulation options. Iron contamination in reagent-grade water or buffers can confound DFO experiments; always use chelexed or ultrapure water and pre-test buffers for iron content when iron homeostasis is the study focus.

Frequently asked questions

What is the difference between deferoxamine and deferoxamine mesylate?

Deferoxamine is the free base form of the compound, while deferoxamine mesylate is the methanesulfonate salt, which offers superior aqueous solubility and greater chemical stability during storage. Research-grade reagents are almost universally supplied as the mesylate salt. When calculating working concentrations, use the molecular weight of the salt form (657.8 g/mol for deferoxamine mesylate vs. 560.7 g/mol for the free base).

How does deferoxamine mimic hypoxia in cell culture experiments?

DFO chelates iron from the catalytic center of prolyl hydroxylase domain (PHD) enzymes, which require Fe²⁺ as a cofactor to hydroxylate and thus destabilize HIF-1α. By depleting this iron, DFO pharmacologically inhibits PHD activity under normoxic conditions, causing HIF-1α to accumulate and translocate to the nucleus, where it activates hypoxia-responsive genes. This approach is referred to as chemical hypoxia and avoids the equipment and variability associated with gas-controlled hypoxia chambers.

Can deferoxamine be used to inhibit ferroptosis, and how does it compare to ferrostatin-1?

Yes, DFO is a standard iron chelation control in ferroptosis experiments. It inhibits ferroptosis upstream by removing the ferric iron required to catalyze lipid peroxidation. Ferrostatin-1 (Fer-1), by contrast, acts as a radical-trapping antioxidant that directly scavenges lipid peroxyl radicals, inhibiting ferroptosis downstream. Using both agents in parallel allows mechanistic dissection of iron-dependent versus radical-propagation steps in the ferroptosis cascade.

What concentration of deferoxamine should I use for in vitro experiments?

Working concentrations vary by application and cell type. For ferroptosis inhibition, 100 µM to 1 mM are commonly reported; for HIF-1α stabilization (chemical hypoxia), 100–500 µM for 4–24 hours is typical. However, concentrations above 500 µM at extended time points can be cytotoxic in some cell lines. It is strongly recommended to perform a dose-response titration and cytotoxicity assessment in your specific cellular model before conducting endpoint experiments.

How should I store prepared deferoxamine solutions?

Prepare aqueous stock solutions in sterile ultrapure water or PBS and aliquot into single-use volumes to avoid repeated freeze-thaw cycles. Store aliquots at –20 °C for up to several weeks, or at –80 °C for longer periods. Protect from light at all times. Discard any aliquots that show discoloration, precipitation, or signs of microbial contamination.

References

1. Cabantchik ZI. Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front Pharmacol. 2014;5:45. doi:10.3389/fphar.2014.00045
2. Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10(1):9-17. doi:10.1038/nchembio.1416
3. Wang H, et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology. 2017;66(2):449-465.
4. Jaakkola P, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468-472. doi:10.1126/science.1059796
5. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13(5):342-355. doi:10.1038/nrc3495

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.